MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

19/03/2019
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study...
13/03/2019
MorphoSys Presents Results for Fiscal Year 2018
07/03/2019
MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208...
27/02/2019
MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA...
19/02/2019
Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to...
19/02/2019
Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His...
05/02/2019
MorphoSys Announces Appointment of David Trexler as President and Member...
31/01/2019
MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab
26/01/2019
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent...
17/01/2019
MorphoSys Announces that its Licensee Janssen has Expanded Clinical...

March 14, 2019
Webcast & Conference Call
Annual Report 2018

Full details

 

 

 

 

Interview with
Simon Moroney, CEO